Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/25254
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2022-03-22T06:59:56Z-
dc.date.available2022-03-22T06:59:56Z-
dc.date.issued2008-05-15-
dc.identifier.citationEker, S. S. vd. (2008). ''Effects of various antidepressants on serum thyroid hormone levels in patients with major depressive disorder''. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 32(4), 955-961.en_US
dc.identifier.issn0278-5846-
dc.identifier.issn1878-4216-
dc.identifier.urihttps://doi.org/10.1016/j.pnpbp.2007.12.029-
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S027858460800016X-
dc.identifier.urihttp://hdl.handle.net/11452/25254-
dc.description.abstractA total of 62 patients with major depressive disorder were analyzed in the study. Patients were evaluated for 11 weeks in an open label design to investigate the differential effects of reboxetine, sertraline and venlafaxine on thyroid hormones. Serum thyrotrophin (TSH), thyroxine (T4) and free (f)T4 levels were measured before and after treatment. All groups showed significant improvement in HAM-D scores. TSH level significantly reduced and T4 level significantly increased in the reboxetine group, however TSH level significantly increased and T4 level significantly reduced in the sertraline group. Percent changes of TSH (p=0.007) and T4 (p=0.001) were significantly different between the reboxetine and sertraline groups. In the sertraline group, baseline TSH levels were correlated with response to treatment as determined by the change in HAM-D scores (p=0.03, r=0.648). There was a significant association between the percent changes in TSH values and the reduction in HAM-D scores in the reboxetine group (p=0.03, r=-0.434). In the whole study group, female patients had lower values of basal T4 compared with men (P=0.043), however percent changes of T4 did not differ between genders. In the treatment-responders significant increase in the reboxetine group and significant decrease in the sertraline group regarding the T4 values were found. We observed that various antidepressants had different effects on thyroid hormone levels and this could be attributed to the different mechanisms of actions of these antidepressants.en_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Scienceen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDepressionen_US
dc.subjectReboxetineen_US
dc.subjectSertralineen_US
dc.subjectThyroid hormoneen_US
dc.subjectVenlafaxineen_US
dc.subjectNorepinephrine reuptake inhibitoren_US
dc.subjectThyrotropin-releasing-hormoneen_US
dc.subjectRat-brainen_US
dc.subjectRefractory depressionen_US
dc.subjectTricyclic antidepressantsen_US
dc.subjectDesipramine treatmenten_US
dc.subjectPsychiatric-patientsen_US
dc.subjectAxisen_US
dc.subjectSerotoninen_US
dc.subjectTriiodothyronineen_US
dc.subjectNeurosciences & neurologyen_US
dc.subjectPharmacology & Pharmacyen_US
dc.subjectPsychiatryen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdrenergic uptake inhibitorsen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntidepressive agentsen_US
dc.subject.meshCyclohexanolsen_US
dc.subject.meshDepressive disorder, majoren_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshMorpholinesen_US
dc.subject.meshPsychiatric status rating scalesen_US
dc.subject.meshSerotonin uptake inhibitorsen_US
dc.titleEffects of various antidepressants on serum thyroid hormone levels in patients with major depressive disorderen_US
dc.typeArticleen_US
dc.identifier.wos000256570400006tr_TR
dc.identifier.scopus2-s2.0-42949146472tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-2593-7196tr_TR
dc.identifier.startpage955tr_TR
dc.identifier.endpage961tr_TR
dc.identifier.volume32tr_TR
dc.identifier.issue4tr_TR
dc.relation.journalProgress in Neuro-Psychopharmacology and Biological Psychiatryen_US
dc.contributor.buuauthorEker, Salih Saygın-
dc.contributor.buuauthorAkkaya, Cengiz-
dc.contributor.buuauthorSarandol, Asli-
dc.contributor.buuauthorCangür, Şengül-
dc.contributor.buuauthorSarandol, Emre-
dc.contributor.buuauthorKırlı, Selçuk-
dc.contributor.researcheridABE-1716-2020tr_TR
dc.contributor.researcheridQ-9477-2019tr_TR
dc.identifier.pubmed18262705tr_TR
dc.subject.wosClinical neurologyen_US
dc.subject.wosNeurosciencesen_US
dc.subject.wosPsychiatryen_US
dc.subject.wosPharmacology & pharmacyen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.indexed.pubmedPubMeden_US
dc.wos.quartileQ2en_US
dc.contributor.scopusid14019347700tr_TR
dc.contributor.scopusid14061855100tr_TR
dc.contributor.scopusid14020405100tr_TR
dc.contributor.scopusid8604063700tr_TR
dc.contributor.scopusid55943324800tr_TR
dc.contributor.scopusid14019745700tr_TR
dc.subject.scopusHyperthyroidism; Myxedema; Levothyroxine Sodiumen_US
dc.subject.emtreeReboxetineen_US
dc.subject.emtreeSertralineen_US
dc.subject.emtreeThyrotropinen_US
dc.subject.emtreeThyroxineen_US
dc.subject.emtreeVenlafaxineen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDrug dose increaseen_US
dc.subject.emtreeDrug effecten_US
dc.subject.emtreeDrug mechanismen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeFree thyroxine indexen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMajor depressionen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeSex differenceen_US
Appears in Collections:PubMed
Scopus
Web of Science

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.